This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These countries offer competitive salaries, a lower cost of living compared to other major tech hubs, and better opportunities for quality of life and work-life balance. As the capital city of the United States, Washington, D.C., Tech talent makes up just over 15% of total tech employment in Ottawa, compared to 11.6%
The venture capital landscape continues to test the discipline and diligence of investors and startups alike. Like many other asset classes, venture capital continues to be impacted by lingering macroeconomic factors affecting funding and liquidity prospects. Interest rates are high.
The firm has been publicly traded in Shanghai since 2000, and this would be Hengruis first major capital raise in over two decades. With a 5,500 member R&D team and 14 research centers, Hengrui has positioned itself as a global leader in biotech innovation, making this one of the most significant healthcare IPOs in APACs 2025 market.
Heading into the second half of 2024, venture capital investors remain cautious as they acknowledge persistent challenging dynamics in the landscape. While dry powder reserves have reached record highs, investors are wary about deploying capital with certain recent macroeconomic factors still fresh in mind.
Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices — as well as their intentions to scale their digital health solutions — to the masses in hopes of securing capital.
2023 so far has revealed ideal conditions for dealmaking due to valuation resets, lessened competition for deals, and new assets coming to market. Around the world, investors are favoring companies that have proven their profitability and that can demonstrate how they have successfully utilized their capital.
billion acquisition of Carmot Therapeutics, a clinical-stage biotechnology company with three GLP-1 assets in clinical production, including its CT-388 lead GLP-1 asset, in the hopes of gaining a competitive footing among Novo Nordisk and Eli Lilly’s products currently on the market (Ozempic, Wegovy, and Mounjaro, respectively).
On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. 2023 was all about learning the use cases of genAI, as companies raced to introduce their own genAI offerings and capabilities into a fiercely competitive market (i.e. OpenAI’s ChatGPT ).
He has a wealth of cross-industry experience in accelerating companies’ growth and raising capital, having spent more than fifteen years in SaaS companies as CFO and COO in industries as varied as manufacturing and biotech. Safaii Board Member Matthew is the founder of Arrowroot Capital. Adi received his B.S. Helena Cisneros Sr.
Pricing: Learn how the price of Stream by AlphaSense ’s premium expert transcript library can keep you ahead of the competition. Do they have a competitive pricing strategy in place? Try AlphaSense for Free To stay ahead of your competition and be agile in your decision-making, you need expert insights. Who uses expert networks?
On the other hand, Biotech heavily underperformed post Q1’21 primarily due to the shifting of focus towards cyclicals and negative sentiments arising as of result of greater regulatory clampdown on transformative deals and drug pricing. Global Healthcare Capital Markets Activity. Healthcare Funding – Normalization of ‘Cash Runways’.
Moderna and BioTech, the pharmaceuticals companies behind the Moderna vaccines for the COVID-19 virus, just announced a new treatment this past December that would greatly reduce the chances of death from melanoma — stirring up substantial interest in investors to funnel capital. a potential cure for skin cancer.
Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices—as well as their intentions to scale their digital health solutions—to the masses in hopes of securing capital.
Capital Ones Acquisition of Discover Financial: $35.3 The FTC has not yet stated whether it intends to block the deal, but some Capital One customers have brought a class-action lawsuit in an attempt to block the merger. Streamline your research workflow, gain the competitive edge, and uncover new opportunities with AlphaSense.
We started this company in – I sort of kind of started it I guess in 2007, but we were really starting to raise capital and get the business off the ground in 2008, which was a horrific economic climate.
A lot of the improvements that I talked about on a macro level, capital efficiency, operations improvements are as important internationally as they are in North America.” – Brian T. Customers have multiyear R&D product road maps, and the competitive environment for customers is more challenging today than it’s ever been.
Biotechnology and synthetic biology: The swift development of mRNA vaccines in 2020 illustrated biotechs unprecedented speed in delivering transformative products. Many Fortune 500 companies now invest in AI, robotics and biotech startups through corporate venture arms, gaining insights and strategic advantage.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content